KLK3 and cancer: Safe and well tolerated with no major AE. Increased CTL response to both peptides and cancer cells was observed in four (40%) patients. Anti-peptide IgG antibodies were also detected in post-vaccination sera of seven (70%) patients. Decrease in PSA level in some patients.